Overall, cellular changes outlined in Figure 4A,B show an increase in expression of markers associated with anti-tumor activity (CD86, CD3, CD4 and CD8) in DFMO and DFMO + GW5074-treated tumors. The gene discussed is CD86; the disease is neoplasm.